Compare Cassava Sciences Inc (FLNA) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Sezzle Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Sezzle Inc trades at $188.69 (market cap $6.34B). The key difference: Sezzle Inc is far larger — about 119.3× Cassava Sciences Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SEZL | |
|---|---|---|
Market Cap | $53.14M | $6.34B |
Sector | Health | Technology |
52-Week High | $4.64 | $188.55 |
52-Week Low | $1.09 | $50.97 |
Enterprise Value | -$33.43M | $6.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Sezzle (SEZL) trades at $193.51, up 6.1% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and trades above key resistance at $194. Fundamentally, the company demonstrates impressive profitability with 30.83% net margins and 91.95% ROE, supported by consistent earnings beats in recent quarters. Recent news highlights product expansion and raised 2026 guidance following strong Q1 results.
Outlook remains positive with accelerating revenue growth and expanding profitability, though valuation multiples appear elevated. Key risks include competitive pressures in fintech and ongoing securities investigation. Analyst consensus is split with 50% buy ratings but average price target of $162 suggests caution about current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
